8 results about "Cancer Model" patented technology

The invention relates to a radionuclide labeled trimer probe 68Ga-TRAP-(FAPI) 3 targeting FAP and a preparation method thereof, Trap is used as a trivalent chelating platform, and three FAPI targeting units are covalently connected by clicking a chemical linking arm to form a trimer structure; the invention further relates to application of the 68Ga-TRAP-(FAPI) 3 probe in preparation of imaging agents or therapeutic drugs for diagnosing FAP positive diseases, experiments prove that the trimer probe is good in affinity and high in stability, and in cell experiments and animal experiments, the uptake rate of FAP positive cells is kept at a high level within 240 minutes; preclinical and preliminary clinical applications show that the tumor detection rate of the < 68 > Ga-TRAP-FAPI 3 in various cancer models is superior to that of < 18 > F-FDG, and compared with < 68 > Ga-FAPI-04, the < 68 > Ga-TRAP-FAPI 3 is clearer to display focuses (particularly tiny metastases), higher in uptake intensity and particularly outstanding in delayed imaging, and the < 68 > Ga-TRAP-FAPI 3 can be used for preparing a medicine for treating cancer. And a novel drug candidate with better performance is provided for precise diagnosis and staging of tumors and subsequent radionuclide targeted therapy.

The invention relates to a multi-cancer-species pathological feature analysis method and system based on a unified framework, and belongs to the field of data processing. In the method, a unified multi-cancer-species analysis framework is constructed, a graph network is introduced to formally characterize the cross-cancer-species (such as 16 cancers) pathological feature similarity, and a NOTEARS algorithm is applied to aggregated pathological features to carry out causal discovery, so that the cross-cancer-species pathological feature similarity is found. Therefore, integrated analysis of association and causality of pathological characteristics of multiple cancer species in a unified space can be realized, isolation of a traditional single cancer species model is overcome, and migration and fusion of knowledge among different cancers are promoted. Meanwhile, the group features similar to the target patient are obtained from the graph network for causal analysis, the biological reasonability and stability of causal inference are remarkably improved, the pathological features with the real driving effect can be more reliably identified, and deep analysis of the pathological features is achieved.

The invention discloses a recombinant bacillus calmette-guerin vaccine medicine for treating bladder cancer, and belongs to the technical field of biological medicine. The recombinant bacillus calmette guerin strain constructed by the invention has a remarkably improved treatment effect on NMIBC, and in a transplanted mouse bladder cancer model and an inducible rat bladder cancer model, the treatment effect of rBCG delta pknG on NMIBC is remarkably superior to that of traditional BCG. Compared with the traditional BCG, the effective rate of the rBCG delta pknG for short-term treatment of NMIBC is increased by 40-50%, and the survival rate of mice is increased by 20%.

The invention provides an antibody specifically binding to human CCR8 or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof provided by the invention can be bound to the surface of a cell expressing CCR8 to block the binding of CCL1-CCR8, and can kill Treg through ADCC, and meanwhile, the antibody or the antigen binding fragment thereof has antitumor activity in a mouse MC38 colon cancer model.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a PI3Kbeta inhibitor in preparation of a medicine for treating prostatic cancer. According to the application, different types of mouse prostate cancer models are constructed, the PI3Kbeta subtype inhibitor is used as a prostate cancer treatment medicine to treat the mouse prostate cancer models, and the result shows that the PI3Kbeta subtype inhibitor can be used for improving the prostate cancer cold tumor microenvironment by enhancing prostate cancer immune T cell infiltration and T cell function enhancement; therefore, a good anti-tumor effect is achieved; on the other hand, the PI3Kbeta subtype inhibitor does not have adverse reaction in animal bodies, and a new thought is provided for treatment of prostatic cancer.

The application discloses a ctPistol ribozyme and application thereof in gene silencing, and belongs to the technical field of biology.The disclosed ctPistol ribozyme can realize effective control of cell phenotype by silencing the expression of key genes.In addition, when applied in a mouse cancer model, the ctPistol realizes a powerful and persistent anti-tumor effect by targeting oncogenic driver genes.As a powerful gene silencing tool and a promising RNA-based therapeutic candidate drug, the ctPistol ribozyme shows an effective way of developing diversified ribozyme-mediated gene control technology.

The present invention relates to a method for diagnosing gastric cancer or predicting the onset thereof. The present invention also relates to a novel gene variant; a method for preparing a gastric cancer model comprising a genetic mutation; a gastric cancer model comprising the genetic mutation; a composition for diagnosing gastric cancer or predicting the onset thereof; a kit for diagnosing gastric cancer or predicting the onset thereof; and a method for screening a drug for treating or preventing gastric cancer. The method for diagnosing gastric cancer and predicting the onset thereof enables early diagnosis of gastric cancer or prediction and prevention of the risk of gastric cancer occurrence prior to disease onset, thereby significantly reducing the incidence and mortality of gastric cancer. In addition, by observing the presence or absence of genetic mutations or changes in frequency of genetic mutation in response to drug treatment, the method can be utilized for molecular mechanism studies for gastric cancer treatment or for the development of drug screening platforms.

The invention provides an application of 4-bromo-N-(1-methyl-3-(4-methylbenzoyl)-2H-isoindole-2-yl) benzenesulfonamide in preparation of an antitumor drug, and relates to the technical field of biomedicine. The invention provides an excellent potential of 4-bromo-N-(1-methyl-3-(4-methylbenzoyl)-2H-isoindoline-2-yl) benzenesulfonamide (ISO-1 for short) in the aspect of resisting colon cancer, and a cell experiment carried out by a CCK-8 method in the application shows that the ISO-1 has a direct killing effect on colon cancer MC38 cells. In a mouse colon cancer model constructed by MC38 cells, the treatment effect of the ISO-1 is further confirmed. Experimental results show that compared with an untreated Control group, the tumor volume of each group of mice treated by ISO-1 is obviously reduced. The ISO-1 treatment obviously prolongs the lifetime of tumor-bearing mice. The lifetime is one of gold standards for measuring the effectiveness of anti-cancer drugs.